New Zealand - engelsk - Medsafe (Medicines Safety Authority)

viatris limited - metformin hydrochloride 500mg;  ;  ; metformin hydrochloride 500mg - film coated tablet - 500 mg - active: metformin hydrochloride 500mg     excipient: dri-klear magnesium stearate povidone active: metformin hydrochloride 500mg excipient: magnesium stearate opadry clear 20c59060 povidone - · treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control · metformin may be used as initial treatment or in sulfonylurea failures either alone or in combination with a sulfonylurea and other oral agents. · adjuvant therapy in insulin dependent diabetes especially if overweight.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

viatris limited - metformin hydrochloride 850mg;  ;  ; metformin hydrochloride 850mg - film coated tablet - 850 mg - active: metformin hydrochloride 850mg     excipient: dri-klear magnesium stearate povidone active: metformin hydrochloride 850mg excipient: magnesium stearate opadry clear 20c59060 povidone - · treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control · metformin may be used as initial treatment or in sulfonylurea failures either alone or in combination with a sulfonylurea and other oral agents. · adjuvant therapy in insulin dependent diabetes especially if overweight.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

viatris limited - montelukast sodium 4.15mg equivalent to montelukast 4 mg - chewable tablet - 4 mg - active: montelukast sodium 4.15mg equivalent to montelukast 4 mg excipient: aspartame cherry flavour 501027 ap0551 colloidal silicon dioxide croscarmellose sodium stear-o-wet m mannitol microcrystalline cellulose - indicated in paediatric patients 2 to 5 years of age for the relief of daytime and night-time symptoms of seasonal allergic rhinitis and perennial allergic rhinitis.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

viatris limited - montelukast sodium 5.19mg equivalent to montelukast 5 mg - chewable tablet - 5 mg - active: montelukast sodium 5.19mg equivalent to montelukast 5 mg excipient: aspartame cherry flavour 501027 ap0551 colloidal silicon dioxide croscarmellose sodium stear-o-wet m mannitol microcrystalline cellulose - indicated in paediatric patients 6 to 14 years of age for the relief of daytime and night-time symptoms of seasonal allergic rhinitis and perennial allergic rhinitis.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

viatris limited - montelukast sodium 10.4mg equivalent to montelukast 10 mg - film coated tablet - 10 mg - active: montelukast sodium 10.4mg equivalent to montelukast 10 mg excipient: colloidal silicon dioxide croscarmellose sodium magnesium stearate mannitol microcrystalline cellulose opadry blue y-22-10538 opadry clear ys-1-7006 sodium laurilsulfate - indicated in adults 15 years of age and older for the relief of day-time and night-time symptoms of seasonal allergic rhinitis and perennial allergic rhinitis.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

viatris limited - tenofovir disoproxil maleate 300mg equivalent to tenofovir disoproxil 245mg - film coated tablet - 300 mg - active: tenofovir disoproxil maleate 300mg equivalent to tenofovir disoproxil 245mg excipient: colloidal silicon dioxide hyprolose lactose monohydrate magnesium stearate microcrystalline cellulose opadry blue 32k505018 - tenofovir disoproxil mylan is indicated for the treatment of chronic hepatitis b in adults and paediatric patients 12 years of age and older.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

viatris limited - tobramycin 80mg - solution for injection - 80 mg/2ml - active: tobramycin 80mg excipient: disodium edetate sodium bisulfate sodium hydroxide sulfuric acid water for injection - tobramycin is indicated for the treatment of serious bacterial infections caused by susceptible strains of the designated microorganisms in the diseases listed below: - septicaemia in the neonate, child, and adult caused by p aeruginosa, e coli, and klebsiella sp - lower respiratory tract infections caused by p aeruginosa, klebsiella sp, enterobacter sp, serratia sp, e coli, and s aureus (penicillinase and non-penicillinase-producing strains) - serious central-nervous-system infections (meningitis) caused by susceptible organisms - intra-abdominal infections, including peritonitis, caused by e coli, klebsiella sp, and enterobacter sp - skin, bone, and skin-structure infections (including burns) caused by p aeruginosa, proteus sp, e coli, klebsiella sp, enterobacter sp, and s aureus - complicated and recurrent urinary tract infections caused by p aeruginosa, proteus sp (indole-positive and indole-negative), e coli, klebsiella sp, enterobacter sp, serratia sp, s aureus, providencia sp, and citrobacter sp.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

viatris limited - valganciclovir hydrochloride 496.3mg equivalent to valganciclovir 450 mg - film coated tablet - 450 mg - active: valganciclovir hydrochloride 496.3mg equivalent to valganciclovir 450 mg excipient: crospovidone microcrystalline cellulose opadry brown 15b565009 purified water stearic acid - for the treatment of cytomegalovirus (cmv) retinitis in acquired immunodeficiency syndrome (aids) patients. for the prevention of cmv disease in solid organ transplant patients at risk.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

viatris limited - zoledronic acid monohydrate 5.33mg equivalent to zolendronic acid (anhydrous) 5mg - solution for infusion - 5 mg/100ml - active: zoledronic acid monohydrate 5.33mg equivalent to zolendronic acid (anhydrous) 5mg excipient: mannitol sodium citrate water for injection - · treatment of osteoporosis in postmenopausal women to reduce the incidence of hip, vertebral and non-vertebral fractures and to increase bone mineral density. · prevention of postmenopausal osteoporosis.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - betahistine dihydrochloride, quantity: 16 mg - tablet, uncoated - excipient ingredients: colloidal anhydrous silica; microcrystalline cellulose; mannitol; citric acid monohydrate; purified talc - meniere's syndrome as defined by the following core symptoms: - vertigo (with nausea/vomiting): - hearing loss (hardness of hearing): - tinnitus.